Market Newsdesk

• AMONG MULTIPLE CLINICAL- AND PRECLINICAL-STAGE NCE (NEW CHEMICAL ENTITY) COMPOUNDS ACQUIRED, ABIVERTINIB IS AN ANCHORING LATE-STAGE DRUG PRODUCT WITH POSITIVE CLINICAL TRIAL RESULTS IN BOTH NON-SMALL CELL LUNG CANCER (NSCLC) AND B-CELL LYMPHOMA:
  • Abivertinib is potentially one of the most effective clinical-stage dual tyrosine kinase inhibitors (TKI), targeting both mutant epidermal growth factor receptor (EGFR) and Bruton’s tyrosine kinase (BTK).
  • Abivertinib is a pyrrolopyrimidine-based irreversible third-generation (3G) EGFR TKI, structurally distinct from all other 3G pyrimidine-based EGFR inhibitors.
  • More than 600 cancer patients have been treated with Abivertinib with a strong safety profile.
  • At the Recommended Phase 2 Dose (RP2D), 300 mg BID, Abivertinib demonstrated favorable clinical efficacy and manageable adverse events in 300 patients with EGFR T790M+ NSCLC as a second line therapy. Positive interim trial results were reported at the American Society of Clinical Oncology (ASCO) Conference (2019) with 90% of cancer patients had tumor size reduction and an 88% DCR (disease control rate). ORR (overall response rate) was 52%, PFS (progression free survival) was 8 months and OS (overall survival) was 25 months. Improved efficacy results have been achieved with the addition of more subjects, longer term follow-up and maturity of the data and will be released soon with plans to pursue a pre-NDA discussion with the FDA.
  • Abivertinib showed similar efficacy as compared to Osimertinib, the only FDA approved third generation EGFR inhibitor, with results from a separate study. However, Abivertinib has a different drug resistant mechanism that could warrant as an alternate to Osimertinib in NSCLC patient treatment to potentially prolong the overall survival.
  • Abivertinib is a potent BTK inhibitor (BTKi) and demonstrated positive clinical trial results in relapsed or refractory (R/R) B-cell malignancies. At 200 mg BID, the ORR was 81.8% (9/11) and the DCR was 100% in an open-label Phase 1 study in relapsed or refractory (R/R) B-Cell lymphoma (NCT03060850).
  • Separate Phase 2 clinical trials (approximately 400 patients enrolled so far) are currently under way in the US (completed with 96 patients enrolled) and Brazil (~300 out of 400 total patients enrolled so far) for the treatment of acute respiratory distress syndrome (ARDS) associated with SARS-CoV-2 viral infection using a dose of Abivertinib 100 mg daily. Results are expected to be available by the end of the summer.
  • Clinical trials to-be-initiated in near future include: a potential Phase 3 study as first line therapy for NSCLC and Phase 2 studies for other cancer and autoimmune disease indications, such as multiple sclerosis, systemic lupus erythematosus, and resistance prostate cancer and hairy cell leukemia (orphan drug indication).
  • Sorrento is seeking major global partnership(s) to co-develop and co-commercialize Abivertinib.

SAN DIEGO, June 02, 2021 (GLOBE NEWSWIRE) — Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that it has completed the acquisition of ACEA Therapeutics Inc. (“ACEA”).

The merger was completed on June 1, 2021 and at such time, ACEA became a wholly owned subsidiary of Sorrento. The total value of the consideration payable to the holders of securities of ACEA in the merger was $38,000,000, subject to certain adjustments for interest expenses, indebtedness, transaction expenses and cash. In total, 5,519,469 shares of Sorrento common stock were issued at closing in satisfaction of certain outstanding indebtedness of ACEA. In addition to the foregoing consideration, and subject to the achievement of certain clinical and sales milestones (as described below), Sorrento will pay the ACEA equity holders (i) up to $450,000,000 in additional payments, subject to the receipt of certain regulatory approvals and achievement of certain net sales targets with respect to the assets acquired in the merger and (ii) with respect to specified royalty-bearing products, five to ten percent of the annual net sales thereof, in each case in accordance with the terms of an earn-out agreement. The amount referenced in clause (i) of the preceding sentence includes the amounts that would have otherwise been due to ACEA under that certain License Agreement, dated July 13, 2020, which agreement terminated in its entirety at the effective time of the merger.

“This is a value-inflection acquisition for Sorrento as we bring in multiple NCE drug product candidates, including the previously licensed Abivertinib as an anchoring small molecule drug product for treating many different cancers and autoimmune diseases,” said Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento. “With broad-spectrum and synergistic infrastructures and expertise in pharmaceutical and biological drug discovery, development and manufacturing, and expanded geographic coverage in China and North America, we envision Sorrento becoming a leading biopharmaceutical company to develop and commercialize innovative medicines that will save and improve lives globally.”

“With perfectly aligned missions, ACEA and Sorrento are both committed to developing innovative drugs and providing therapeutic solutions for unmet medical needs. The successful integration of ACEA small molecule drug pipelines to Sorrento large molecule and cell therapy platforms will significantly strengthen and facilitate the innovative drug development in the field of cancer and autoimmune diseases,” said Xiao Xu, M.D, President of ACEA Therapeutics.

About Sorrento Therapeutics, Inc.

Sorrento is a clinical stage, antibody-centric, biopharmaceutical company developing new therapies to treat cancers and COVID-19. Sorrento’s multimodal, multipronged approach to fighting cancer is made possible by its extensive immuno-oncology platforms, including key assets such as fully human antibodies (“G-MAB™ library”), clinical stage immuno-cellular therapies (“CAR-T”, “DAR-T™”), antibody-drug conjugates (“ADCs”), and clinical stage oncolytic virus (“Seprehvir™”). Sorrento is also developing potential antiviral therapies and vaccines against coronaviruses, including COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVI-MSC™ and COVIDROPS™; and diagnostic test solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.

Sorrento’s commitment to life-enhancing therapies for patients is also demonstrated by our effort to advance a first-in-class (TRPV1 agonist) non-opioid pain management small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, and to commercialize ZTlido^® (lidocaine topical system) 1.8% for the treatment of post-herpetic neuralgia. RTX has completed a Phase 1B trial for intractable pain associated with cancer and a Phase 1B trial in osteoarthritis patients. SEMDEXA is in a pivotal Phase 3 trial for the treatment of lumbosacral radicular pain, or sciatica. ZTlido^® was approved by the FDA on February 28, 2018.

For more information visit www.sorrentotherapeutics.com.

About ACEA Therapeutics Inc.

ACEA Therapeutics is committed to developing and delivering innovative treatments to improve the lives of patients with life-threatening diseases. ACEA has expanded drug discovery efforts to encompass development in both targeted and immunotherapy areas. Alongside a robust R&D organization, ACEA has established drug manufacturing and commercial capabilities in China to support its long-term growth. This infrastructure provides ACEA greater control over drug supply chain to make sure products are delivered to patients on-time and at the highest quality. ACEA is well positioned to deliver on its promise to bring innovative treatments to patients living with life-threatening diseases while creating value for shareholders, employees, and society.

For more information visit www.aceatherapeutics.com

Forward-Looking Statements

This press release and any statements made for and during any presentation or meeting contain forward-looking statements related to Sorrento Therapeutics, Inc., under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the potential effects that the acquisition of ACEA may have on Sorrento’s business and product candidate pipeline; Sorrento’s ability to combine ACEA’s technology with Sorrento’s technology and manufacturing capabilities; and Sorrento’s potential position in the biopharmaceutical industry. Risks and uncertainties that could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements include, but are not limited to: potential adverse reactions or changes to business relationships resulting from the completion of the merger; unexpected costs, charges or expenses resulting from the merger; risks related to Sorrento’s technologies and prospects, including, but not limited to: risks related to seeking regulatory approvals; clinical development risks, including risks in the progress, timing, cost, and results of clinical trials and product development programs; risk of difficulties or delays in obtaining regulatory approvals; risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval; risks that prior test, study and trial results may not be replicated in future studies and trials; risks of manufacturing and supplying drug product; risks related to leveraging the expertise of its employees, subsidiaries, affiliates and partners to assist Sorrento in the execution of its therapeutic antibody product candidate strategies; risks related to the global impact of COVID-19; and other risks that are described in Sorrento’s most recent periodic reports filed with the Securities and Exchange Commission, including Sorrento’s Annual Report on Form 10-K for the year ended December 31, 2020, and subsequent Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release and we undertake no obligation to update any forward-looking statement in this press release except as required by law.

Media and Investor Relations Contact


Alexis Nahama, DVM (SVP Corporate Development)
Email: [email protected]

Sorrento^® and the Sorrento logo are registered trademarks of Sorrento Therapeutics, Inc.

G-MAB™, DAR-T™, SOFUSA™, COVIGUARD™, COVI-AMG™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™, COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento Therapeutics, Inc.

SEMDEXA™ is a trademark of Semnur Pharmaceuticals, Inc.

ZTlido^® is a registered trademark owned by Scilex Pharmaceuticals Inc.

All other trademarks are the property of their respective owners.

©2021 Sorrento Therapeutics, Inc. All Rights Reserved.

BURLINGTON, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Avid® (Nasdaq: AVID) today announced a multi-year partnership with Remote Picture Labs (RPL), a leading provider of remote editing solutions for the Hollywood film and television industry. This agreement enables RPL to offer a virtual film and television post production solution that allows editors, assistant editors and producers to collaborate from anywhere using Avid’s Media Composer® software and Avid NEXIS® storage products offered as a service to its customers. RPL has shifted its business model to address the changing landscape as media companies gravitate toward “as-a-service” offerings to support an increasingly distributed workforce, moving from perpetual licenses to subscription with Avid.

Originally developed so that edit teams could work during the COVID-19 pandemic, the RPL solution provides all the system performance and functionality of traditional Avid workstations. Each virtualized client runs on RPL’s high-performance private cloud in a robust, secure environment that possesses the same picture and audio quality and throughput found in on-premises edit bays. This continuity enables the seamless transition to a remote, collaborative environment, with content security assured through multi-factor authentication and AES-256 encryption.

“A primary consideration from the outset was to let edit teams use their existing media and projects,” said Erik Beauchamp, Chief Technical Officer at Remote Picture Labs. “Our goal was to provide an experience identical to that of a traditional edit bay so that workflows can function just as they always have. Partnering with Avid made it possible, with additional benefits including editorial cost savings of up to 20 percent and the ability to hire editors wherever they might be located, since they no longer need to be in the East or West Coast talent pools. Though it was born of necessity during the COVID-19 pandemic, our solution has proven to be a game-changer for all film and television post production moving forward.”

Built around Avid’s award-winning Media Composer video editing software and Avid NEXIS media storage, RPL’s virtual workstations can be used as part of either a completely remote or a hybrid solution with some people working on premises and others remotely. The software-based platform gives editing teams access to the latest Media Composer features as soon as they’re available and provides a common experience whether the editor is working in a post facility or studio or from home. Multiple workstations can be integrated on the same project, making the RPL solution ideal for remote collaborative editing of premium live sports, studio shows, episodic television and feature films.

“As the rental market has evolved and media companies had to immediately pivot to work-from-anywhere models, the days of delivering rental equipment in person changed overnight,” said Raymond Thompson, Senior Director Partner and Industry Marketing at Avid. “RPL responded by developing its own hosted remote editing solution featuring Avid Media Composer and Avid NEXIS and has helped its clients’ productions continue during the pandemic. Through our long-term technology partnership, we can continue to extend remote capabilities to the post production community in the post-pandemic future.”

For more information about Avid Media Composer and Avid NEXIS, visit https://www.avid.com/media-composer and https://www.avid.com/products/avid-nexis.

About Avid

Avid delivers the most open and efficient media platform, connecting content creation with collaboration, asset protection, distribution, and consumption. Avid’s preeminent customer community uses Avid’s comprehensive tools and workflow solutions to create, distribute and monetize the most watched, loved and listened to media in the world—from prestigious and award-winning feature films to popular television shows, news programs and televised sporting events, and celebrated music recordings and live concerts. With the most flexible deployment and pricing options, Avid’s industry-leading solutions include Media Composer^®, Pro Tools^®, Avid NEXIS^®, MediaCentral^®, iNEWS^®, AirSpeed^®, Sibelius^®, Avid VENUE^™, FastServe^®, and Maestro^™. For more information about Avid solutions and services, visit www.avid.com, connect with Avid on Facebook, Instagram, Twitter, YouTube, LinkedIn, or subscribe to Avid Blogs.

About Remote Picture Labs

Based in Burbank, Calif., Remote Picture Labs was launched in March 2020 as a joint venture by Creative Mobile Solutions, the Emmy Award-winning developer of tapeless environments for live events and studio shows, and J/KAM Digital, a provider of innovative editing and shared storage solutions for more than 25 years. RPL is focused on providing media companies and tier-one sports organizations with high-performance remote collaborative editing solutions over private cloud infrastructure. The company’s solution offers a number of advantages over traditional, on-premises editing environments, including fixed pricing and workflow scalability, flexibility and portability. Many producers of nationally broadcast television shows and sporting events, including “Jimmy Kimmel Live!” and Fox Sports, have now discovered the RPL difference.

© 2021 Avid Technology, Inc. All rights reserved. Avid, the Avid logo, Avid NEXIS, FastServe, AirSpeed, iNEWS, Maestro, MediaCentral, Media Composer, Pro Tools, Avid VENUE, and Sibelius are trademarks or registered trademarks of Avid Technology, Inc. or its subsidiaries in the United States and/or other countries. All other trademarks are the property of their respective owners. Product features, specifications, system requirements and availability are subject to change without notice.

PR Contacts

Avid
Dave Smith
[email protected]
978.502.9607

Red Lorry Yellow Lorry (Avid’s PR agency)  
Martin Izzard—UK
Casey Love—USA
[email protected]

Exclusive rating recognizes
Progress Accelerate
as a state-of-the-art partner program

BEDFORD, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Progress (NASDAQ: PRGS), the leading provider of products to develop, deploy and manage high-impact business applications, today announced it has received a 5-Star rating from CRN®, a brand of The Channel Company, in its 2021 Partner Program Guide. This is Progress’ ninth 5-star rating and 12th year in the guide.

This annual guide provides a conclusive list of the most distinguished partner programs from leading technology companies that provide products and services through the IT channel. The 5-Star rating is awarded to an exclusive group of companies that offer solution providers the best programs, going above and beyond in their commitment to their partner communities.

“As innovation continues to fuel the speed and intricacy of technology, solution providers need partners that can keep up with and support their developing business,” said Blaine Raddon, CEO of The Channel Company. “CRN’s 2021 Partner Program Guide gives insight into the strengths of each organization’s program to recognize those that continually support and push positive change inside the IT channel.”

The Progress® Accelerate™ Partner Program provides a robust set of tools and resources to ensure Progress partners get all the support they need to succeed. It consists of three distinct levels—Titanium, Gold and Silver—along with six specialties, and offers a wide range of benefits including marketing tools and programs, training and enablement, sales account management and incentive programs.

Each year, CRN develops its Partner Program Guide to provide the channel community with a detailed look at the partner programs offered by IT manufacturers, software developers, service companies and distributors. Vendors are scored based on investments in program offerings, partner profitability, partner training, education and support, marketing programs and resources, sales support and communication.

“We are honored to be included on this prestigious list of companies with stellar partner programs,” said Gary Quinn, SVP, Core Field Operations, Progress. “The Progress partner ecosystem nurtures tens of thousands of businesses and millions of users around the globe and is vital to our ongoing global growth strategy. We’ve recognized the importance of our partners by creating a program that makes it easier for them to grow, compete and win.”

Progress’ partner program, leadership and technology have previously been recognized by CRN’s Mobility 100, Channel Chiefs, Women of the Channel, Tech Innovators and Partner Program Guides. The 2021 Partner Program Guide is featured in the April 2021 issue of CRN and online at www.CRN.com/PPG.  

To learn more about the Progress Accelerate Partner Program, visit https://www.progress.com/partners.

Additional Resources

• Follow Progress on Twitter, Facebook and LinkedIn
• Read the Progress blog

About Progress

Progress (NASDAQ: PRGS) provides the leading products to develop, deploy and manage high-impact business applications. Our comprehensive product stack is designed to make technology teams more productive, and we have a deep commitment to the developer community, both open source and commercial alike. With Progress, organizations can accelerate the creation and delivery of strategic business applications, automate the process by which apps are configured, deployed and scaled, and make critical data and content more accessible and secure – leading to competitive differentiation and business success. Over 1,700 independent software vendors, 100,000+ enterprise customers, and a three-million-strong developer community rely on Progress to power their applications. Learn about Progress at www.progress.com or +1-800-477-6473.

Progress and Progress Accelerate are trademarks or registered trademarks of Progress Software Corporation and/or one of its subsidiaries or affiliates in the US and other countries. Any other trademarks contained herein are the property of their respective owners.

Press Contact:           
Kim Baker           
Progress        
+1 781-280-4000           
[email protected]

• Company to present new preclinical data in myotonic dystrophy type 1 to support a path to enter the clinic in 2022, as well as provide updates on the Huntington’s disease program and unveil a new oncology program targeting high-value genetic driver mutations
• KOLs in peptide nucleic acids (PNAs) and Huntington’s disease to also present
• Investors and analysts suggested to pre-register for the event
  

PITTSBURGH, June 02, 2021 (GLOBE NEWSWIRE) — NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of precision genetic medicines, today announced that it will host a virtual R&D day for investors and analysts on Tuesday, June 8, 2021 at 12:30 p.m. EDT.

The event will feature presentations from the NeuBase management team and the following Key Opinion Leaders:

• Peter Nielsen, Ph.D., is a leading expert in gene targeting, RNA interference, and chemical replication and translation and was one of the inventors of PNAs, the backbone of NeuBase’s PATrOL™ platform.
• Robert M. Friedlander, M.D., M.A., is intricately involved in basic and translational neuroscience research initiatives, and his work has developed new potential approaches for treatments including Huntington’s disease.

NeuBase will present new data for the Company’s pipeline – including myotonic dystrophy type 1 (DM1), Huntington’s disease (HD), and its new oncology program.

Using the Company’s proprietary PATrOL™ platform, NeuBase is designing precision genetic medicines to activate, silence, or edit genes, as appropriate, depending on the underlying genetic mutation driving disease. This unifying platform capability is uniquely positioned to create a scalable pipeline of new medicines to address previously untreatable diseases.

A live Q&A session will follow the formal presentations. To register for NeuBase’s R&D Day, please click here.

KOL Biographies

Peter Nielsen, Ph.D., is currently a full professor at the University of Copenhagen, where his lab focuses on PNAs in regard to drug discovery, gene targeting, antisense principles, and cellular and in vivo delivery and administration of biopharmaceuticals. He is the co-author of more than 400 scientific papers and reviews as well as co-inventor on more than 20 patents and patent applications. He was Editor-in-Chief on the journal “Artificial DNA.” Dr. Nielsen has received several national and international scientific prizes including the NovoNordic Foundation, the Lundbeck Foundation, and the Institute Curie Jeanne Loubaresse prize. In addition to his esteemed academic career, Dr. Nielsen is the co-founder of two biotech companies in Denmark and is a member of EMBO and the Danish Academy of Technical Sciences. Dr. Nielsen is a member of the Scientific Advisory Board of NeuBase.

Robert Friedlander, M.D., M.A., is the Walter E. Dandy Distinguished Professor and Chair of the University of Pittsburgh Department of Neurological Surgery and Co-Director of the UPMC Neurological Institute. Before coming to the University of Pittsburgh, Dr. Friedlander was a professor at Harvard Medical School. He was also Vice-Chairman of Neurosurgery, Associate Director of Cerebrovascular Surgery and Co-Director of the Neuroscience Research Center at the Brigham and Women’s Hospital in Boston. Dr. Friedlander has received a number of significant academic awards; most significantly, he was elected into the prestigious National Academy of Medicine in 2018. He also received the Bayer Cerebrovascular Award from the Joint Section of Cerebrovascular Surgery, the International Charcot Prize for Motor Neuron Diseases, the Award from the Academy of Neurological Surgeons, and the H. Richard Winn Prize from the Society of Neurological Surgeons. Dr. Friedlander is an elected member of the prestigious American Society for Clinical Investigation and the Association of American Physicians. Dr. Friedlander is a member and Chair of the Scientific Advisory Board of NeuBase.

About NeuBase Therapeutics

NeuBase is accelerating the genetic revolution by developing a new class of precision genetic medicines which can be designed to increase, decrease, or change gene function, as appropriate, to resolve genetic defects that drive disease. NeuBase’s targeted PATrOL™ therapies are centered around its proprietary drug scaffold to address genetic diseases at the DNA or RNA level by combining the highly targeted approach of traditional genetic therapies with the broad organ distribution capabilities of small molecules. With an initial focus on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncologic disorders, NeuBase is committed to redefining medicine for the millions of patients with both common and rare conditions. To learn more, visit www.neubasetherapeutics.com.

Use of Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by use of words such as “will,” “would,” “anticipate,” “expect,” “believe,” “designed,” “plan,” or “intend,” the negative of these terms, and similar references to future periods. These forward-looking statements include, among others, those related to the plan to provide updates on the Company’s development pipeline, including the myotonic dystrophy type 1 (DM1) and Huntington’s disease (HD) programs and an oncology program targeting high value genetic driver mutations, at an R&D day in June 2021 and the prospects of the Company’s proprietary PATrOL™ platform. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including those risk factors contained in our filings with the U.S. Securities and Exchange Commission (the “SEC”), may cause our actual results to differ from those expressed in forward-looking statements. The Company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements of the Company could differ materially from those described in or implied by the statements in this press release, including: the Company’s plans to develop and commercialize its product candidates; the timing of initiation of the Company’s planned clinical trials; the risks that prior data will not be replicated in future studies; the timing of any planned investigational new drug application or new drug application; the Company’s plans to research, develop and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s commercialization, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as those risk factors contained in our filings with the SEC. Except as otherwise required by law, the Company disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date hereof, whether as a result of new information, future events or circumstances or otherwise.

NeuBase Investor Contact:

Dan Ferry
Managing Director
LifeSci Advisors, LLC
[email protected]
OP: (617) 430-7576

NeuBase Media Contact:

Jessica Yingling, Ph.D.
Little Dog Communications Inc.
(858) 344-8091
[email protected]

SHELTON, Conn., June 02, 2021 (GLOBE NEWSWIRE) — Acme United Corporation (NYSE American: ACU) announced today that it will present virtually at the LD Micro Invitational XI event on Tuesday, June 8 at 12:00pm EDT. Walter Johnsen, Chairman and Chief Executive Officer of Acme United, will give the presentation.

To watch Acme United’s presentation, register here.

About Acme United

ACME UNITED CORPORATION is a leading worldwide supplier of innovative safety solutions and cutting technology to the school, home, office, hardware, sporting goods, and industrial markets. Its leading brands include First Aid Only®, First Aid Central®, PhysiciansCare®, Pac-Kit®, Spill Magic®, Westcott®, Clauss®, Camillus®, Cuda®, DMT®, and Med-Nap.

For more information, visit www.acmeunited.com.

Contact:

Paul G. Driscoll
Acme United Corporation
1 Waterview Drive Shelton, CT 06484
203-254-6060

CHICAGO, June 02, 2021 (GLOBE NEWSWIRE) — Mondelēz International, Inc. (Nasdaq: MDLZ) announced that Luca Zaramella, Chief Financial Officer, and Vinzenz Gruber, EVP & President Europe, will present at the Deutsche Bank Global Consumer Conference, on June 9 at 07:00 a.m. CT.

A listen-only webcast will be provided at www.mondelezinternational.com and a replay of the event will also be available on the company’s website.

About Mondelēz International

Mondelēz International, Inc. (Nasdaq: MDLZ) empowers people to snack right in over 150 countries around the world. With 2020 net revenues of approximately $27 billion, MDLZ is leading the future of snacking with iconic global and local brands such as OREO, belVita and LU biscuits; Cadbury Dairy Milk, Milka and Toblerone chocolate; Sour Patch Kids candy and Trident gum. Mondelēz International is a proud member of the Standard and Poor’s 500, Nasdaq 100 and Dow Jones Sustainability Index. Visit www.mondelezinternational.com or follow the company on Twitter at www.twitter.com/MDLZ.

STMicroelectronics and
Metalenz
Partner to Transform Optical Sensing

for Consumer, Automotive, and Industrial Applications

• Agreement encompasses development of manufacturing processes,
  
  industrialization of meta-surface optics, and technology
  licensing

• Revolutionary flat-lens technology brings performance,
  power, size,
  
  and cost advantages to complex optical
  systems

Geneva, Switzerland; and Boston, MA, USA
– June 2, 2021 — STMicroelectronics (NYSE: STM), a global semiconductor leader serving customers across the spectrum of electronics applications, and Metalenz Inc., the pioneer in meta-surface design and commercialization, today announced a co-development and license agreement that will see ST develop manufacturing processes for Metalenz’s meta-optics technology for next-generation smartphones, consumer devices, healthcare, and automotive applications. Metalenz is a spin-out of the group of Federico Capasso at Harvard University, where the technology was invented. This breakthrough technology is expected to be ready for mass production by the end of this year.

Metalenz’s multifunctional meta-surface optics enable new forms of sensing for the next generation of smartphones and other consumer devices, as well as healthcare and automotive applications. For example a camera built around this new flat-lens technology can collect more light for brighter images and produce images of the same or better quality than traditional refractive lenses while consuming less power and taking up less space.

ST will integrate Metalenz’s meta-surface optics technology into ST’s existing diffractive optics manufacturing process at its 300mm wafer fab in Crolles, France, leveraging ST’s position at the forefront of the fast-growing Near-Infrared (NIR) optical sensing market. Today ST leads the market for time-of-flight (ToF) proximity and distance sensors with over 1 billion devices shipped to customers.

Eric Aussedat, Executive Vice President & General Manager of ST’s Imaging Division, said, “With its advantages in power, efficiency, and performance, multifunctional optics technology can be a game changer for the next generation of optical sensors used in smartphones and other consumer devices, as well as healthcare and automotive applications. In combining Metalenz’s advances with our proprietary technology, manufactured in our state-of-the-art 300mm production facility in Crolles,this partnership will support ST’s continued offering of the most innovative and advanced optical-sensing solutions to its customers.”

“We are thrilled to be working with an industry leader like ST. The technology developed by
Metalenz
is a perfect complement to ST’s advanced capabilities and market position,” said Dr. Rob Devlin, CEO and co-founder of Metalenz. “We adopted a fabless business model so that we can focus on the innovation and design of revolutionary optics to transform sensing from smartphones to automobiles. Working with ST enables us to expand our product offering while leveraging ST’s high-volume fabrication capability and enables ST’s already differentiated product lines to reach new heights with Metalenz inside.”

Note to
editors

The technology used in today’s smartphones is changing and developing at a very fast rate to squeeze more and better functionality into less space. Still, the lenses remain essentially unchanged since medieval times. That’s now changing, with meta-surface optics introducing a new breed of lens, which works on very different fundamental principles. Instead of using bulkier curved surfaces, meta-surface optics combine multiple complex optical functions in a single flat layer. This shrinks the size of each lens element while also cutting the number of lens elements needed, dramatically reducing the size of the optical lens, the number of components, the complexity of assembly, and the overall cost.

The technology developed by Metalenz is a perfect complement to ST’s advanced capabilities. Combining semiconductor manufacturing and optics, ST will use advanced lithographic masks to build tunable diffractive-wavefront layers on a meta-surface in a semiconductor wafer fab. Like silicon ICs, the flat meta-surface lenses are processed in a semiconductor clean room using the same manufacturing technology. The lenses will feature nanostructures one-thousandth the width of a human hair. These nanostructures appropriately bend light rays to realize in a single layer the same functionality as a complex multi-element refractive lens system.

This technology is initially targeted at the fast-growing NIR market. NIR wavelengths are used in all the 3D sensing functions, such as face identification, autofocus assist, mini-LIDAR, and AR/VR depth mapping, that are becoming standard in today’s smartphone. Given the benefits, optical lenses made in a semiconductor wafer fab could someday be as common as traditional refractive lenses.

About STMicroelectronics

At ST, we are 46,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An independent device manufacturer, we work with more than 100,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of the Internet of Things and 5G technology. Further information can be found at www.st.com.

About
Metalenz

Metalenz, founded in 2016, is the first company to commercialize meta-optics. Our meta-surface technology provides complex, multifunctional optical performance in a single semiconductor layer and enables moving large-scale production of optics into semiconductor foundries—printing lenses like computer chips. As a fabless semiconductor company, Metalenz is focused on the design and unique applications of meta-optics, transforming sensing across consumer, healthcare, and automotive applications. 

The company has the exclusive worldwide license to the portfolio of foundational intellectual property relating to metasurfaces developed in the Capasso Lab at Harvard University and has more than 20 patents on innovations that simplify and improve optical devices across multiple markets.  For more information, please visit https://www.metalenz.com/

For Press Information Contact:

Michael Markowitz
Director Technical Media Relations
STMicroelectronics
Tel: +1 781 591 0354
Email: michael.markowitz@st.com

Carlos Calvo
VP of Product
Metalenz
Tel: +1 508 333 8901
Email: [email protected]

Attachments

• T4364D — June 2 2021 — ST Metalenz optical sensing_IMAGE
• T4364D — June 2 2021 — ST Metalenz optical sensing_FINAL FOR PUBLICATION